Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The study investigates the effect of 14 days of twice daily doses of ARV-1801 or placebo in combination with meropenem or ceftazidime in patients hospitalized with melioidosis.
Epistemonikos ID: 49f25e968c5771fcc39140f3ee358bb83c779537
First added on: May 09, 2024